PT1059921E - Utilizacao de compostos macrolitos para o tratamento de sdra - Google Patents

Utilizacao de compostos macrolitos para o tratamento de sdra

Info

Publication number
PT1059921E
PT1059921E PT99937870T PT99937870T PT1059921E PT 1059921 E PT1059921 E PT 1059921E PT 99937870 T PT99937870 T PT 99937870T PT 99937870 T PT99937870 T PT 99937870T PT 1059921 E PT1059921 E PT 1059921E
Authority
PT
Portugal
Prior art keywords
compounds
treatment
macrolite
ards
utilization
Prior art date
Application number
PT99937870T
Other languages
English (en)
Inventor
Itsuo Nagatomi
Tadatsura Koshika
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT1059921E publication Critical patent/PT1059921E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT99937870T 1998-03-06 1999-03-04 Utilizacao de compostos macrolitos para o tratamento de sdra PT1059921E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP2231A AUPP223198A0 (en) 1998-03-06 1998-03-06 New use

Publications (1)

Publication Number Publication Date
PT1059921E true PT1059921E (pt) 2003-11-28

Family

ID=3806495

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99937870T PT1059921E (pt) 1998-03-06 1999-03-04 Utilizacao de compostos macrolitos para o tratamento de sdra

Country Status (14)

Country Link
US (1) US6333334B1 (pt)
EP (1) EP1059921B1 (pt)
JP (1) JP3367105B2 (pt)
KR (1) KR100395571B1 (pt)
CN (1) CN1133429C (pt)
AT (1) ATE244008T1 (pt)
AU (1) AUPP223198A0 (pt)
BR (1) BR9908796A (pt)
CA (1) CA2322027C (pt)
DE (1) DE69909257T2 (pt)
DK (1) DK1059921T3 (pt)
ES (1) ES2196840T3 (pt)
PT (1) PT1059921E (pt)
WO (1) WO1999044597A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
SI2071917T1 (sl) * 2006-09-29 2013-03-29 Infa S.A. Pakirni sistem za farmacevtske sestavke in komplet za intravensko aplikacijo
EP2068865A4 (en) * 2006-12-28 2011-08-10 Limerick Biopharma Inc METHOD AND COMPOSITIONS FOR THERAPY TREATMENT
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
CN101011414B (zh) * 2007-01-29 2010-07-21 褚福明 一种肺脑合剂药物
CA2693338A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
CN101810633B (zh) * 2010-03-31 2011-12-14 湖北丝宝药业有限公司 地红霉素在制备治疗慢性非感染性呼吸道疾病药物的用途
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
MX2022014958A (es) * 2020-05-28 2023-04-13 Phor Med Inc Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent

Also Published As

Publication number Publication date
ES2196840T3 (es) 2003-12-16
CN1133429C (zh) 2004-01-07
JP3367105B2 (ja) 2003-01-14
US6333334B1 (en) 2001-12-25
DE69909257T2 (de) 2004-02-19
JP2001520682A (ja) 2001-10-30
CA2322027A1 (en) 1999-09-10
DE69909257D1 (de) 2003-08-07
AUPP223198A0 (en) 1998-04-02
KR100395571B1 (ko) 2003-08-21
WO1999044597A2 (en) 1999-09-10
ATE244008T1 (de) 2003-07-15
BR9908796A (pt) 2000-10-31
CA2322027C (en) 2009-05-12
KR20010041046A (ko) 2001-05-15
CN1292695A (zh) 2001-04-25
HK1036406A1 (en) 2002-01-04
WO1999044597A3 (en) 1999-12-29
EP1059921B1 (en) 2003-07-02
DK1059921T3 (da) 2003-10-27
EP1059921A2 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
BR0009830A (pt) Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele
BR0110024A (pt) Derivados de ecteinascidina antitumorais
NL990030I1 (nl) Derivaten en analogen van 2-deoxy-2,3-didehydro-N-acetylneuraminezuur en het gebruik ervan als antivirale middelen.
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
AU5624699A (en) Use of 5ht-6 antagonists
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
DK1059921T3 (da) Anvendelse af macrolidforbindelser til behandling af ARDS
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
NO20030802L (no) Aminoalkoksybenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte for deres fremstilling og preparater inneholdende de samme
DE60116106D1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
AU2002252134A1 (en) Methods of treating irritable bowel syndrome and functional dyspepsia
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
NO982562L (no) Sammensetning for behandling av smerte
TR200103430T2 (tr) Aminoalkil ile ikame edilmiş (benzodioksan, benzofuran veya benzopiran) türevleri
NO882030D0 (no) Fremgangsmaate til fremstilling av hydrasinderivater til bruk som antihypertensivt middel.
DE69114707D1 (de) Neue alpha-glukosidaseinhibitoren.